Physician profile
Katherine Smentkowski
NPI 1336567353
$6,585.86
in general payments reported to CMS, 2019-2025
42 companies · $1,720 in 2025
The $1,720 reported for 2025 was more than what 76% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.08 · 2021: $769 · 2022: $2,120 · 2023: $1,183 · 2024: $720 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,511 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,510.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $876.01 | 2023-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $805.54 | 2021-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $571.38 | 2021-2025 | Myrbetriq, Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $441.66 | 2019-2025 | |
| Abbvie INC. | $417.98 | 2021-2025 | Botox |
| Urovant Sciences INC | $317.72 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $317.68 | 2022-2025 | Pylarify |
| Boston Scientific Corporation | $278.15 | 2019-2025 | Moses, Ams 700 Cxr Rte Kit, Greenlight Xps |
| Tolmar Pharmaceuticals, INC. | $238.94 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $229.44 | 2021-2023 | Edex, Xiaflex, Aveed |
| Urogen Pharma, INC. | $215.74 | 2021-2025 | |
| Tolmar, INC. | $189.94 | 2023-2025 | Jatenzo, Eligard |
| Myovant Sciences INC. | $173.97 | 2021-2022 | |
| Teleflex LLC | $138.74 | 2022 | |
| Immunitybio, INC. | $135.17 | 2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $133.24 | 2021-2025 | |
| Antares Pharma, INC. | $129.96 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Coloplast Corp | $103.40 | 2021-2025 | |
| Dendreon Pharmaceuticals LLC | $94.86 | 2019-2023 | Provenge |
| Merck Sharp & Dohme LLC | $80.51 | 2021-2024 | Keytruda |
| Mission Pharmacal Company | $78.15 | 2022-2023 | Uribel |
| Novartis Pharmaceuticals Corporation | $70.85 | 2022-2025 | |
| Tempus Ai, INC | $69.28 | 2024 | Xt Cdx |
| Olympus America INC. | $46.63 | 2023-2024 | Itind System |
| Convatec INC. | $41.97 | 2021 | |
| Bioprotect Medical, INC. | $40.77 | 2025 | Bioprotect Balloon Implant System |
| Alnylam Pharmaceuticals INC. | $37.26 | 2022-2025 | Givlaari |
| Myriad Genetic Laboratories, INC. | $32.29 | 2021-2022 | |
| Medtronic, INC. | $30.77 | 2023-2024 | Interstim |
| Allergan, INC. | $26.73 | 2022 | |
| Accord Healthcare, INC. | $24.73 | 2025 | |
| Dentsply Ih Ab | $23.75 | 2025 | Lofric |
| Halozyme INC | $22.86 | 2023 | |
| Palette Life Sciences, INC. | $22.23 | 2022 | |
| Civco Medical Instruments | $20.05 | 2024 | |
| Blue Earth Diagnostics | $19.60 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.23 | 2024 | Xifaxan |
| Amgen INC. | $15.28 | 2023 | Prolia |
| Endo USA, INC. | $15.05 | 2025 | Aveed, Xiaflex |
| Travere Therapeutics, INC. | $14.56 | 2021 | |
| Telix Pharmaceuticals | $13.76 | 2022 | |
| Millicent US INC | $13.03 | 2023 | Intrarosa, Femring |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Smentkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.